<DOC>
	<DOCNO>NCT01261481</DOCNO>
	<brief_summary>The purpose study compare relative bioavailability pharmacokinetics tolvaptan 15 mg tablet administer orally versus tolvaptan via nasogastric ( NG ) tube healthy male female subject . This study open 2-treatment , 2-period , 2-sequence crossover study compare relative bioavailability tolvaptan tablet tolvaptan give via nasogastric tube 28 healthy adult . Subjects randomize one two treatment sequence ; either tolvaptan oral tablet swallow intact follow tablet crush administered via nasogastric tube , reverse sequence . Serial pharmacokinetic sample collect follow tolvaptan administration safety assessment perform . The relative bioavailability tolvaptan administer via nasogastric tube compare tolvaptan tablet swallow intact .</brief_summary>
	<brief_title>Bioavailability Study Comparing Tolvaptan Administered Via Nasogastric Tube Tolvaptan Tablets Swallowed Intact</brief_title>
	<detailed_description>This study open 2-treatment , 2-period , 2-sequence crossover study compare relative bioavailability tolvaptan tablet tolvaptan NG 28 healthy adult . The study conduct University North Carolina ( UNC ) Hospital Clinical Translational Research Center ( CTRC ) . The study consist three phase ( screen two drug administration visit ) . Subjects randomized one two treatment sequence ; either tolvaptan oral tablet swallow intact follow tablet crush administered via nasogastric ( NG ) tube , reverse sequence . Because enrollment stagger male female enrol , randomization block ( group 4 ) minimize imbalance assignment two sequence enrollment period , use bidirectional fashion balance gender , male enter low subject number ( # 1 , # 2 , etc . ) , females high subject number ( # 32 , # 31 , etc . ) randomization schedule . The biomedical informatics core generate randomization schedule . During inpatient phase , pharmacokinetic parameter monitor 36 hour . Subjects remain CTRC 24 hour drug administration allow adequate pharmacokinetic sampling . Subjects return clinic study day 2 9 study schedule 30 36 hour blood sample . Subjects undergo one-week washout period cross alternative mode administration . Subjects discharge study vital sign check study day 2 9 study schedule 36 hour , assume subject hemodynamically stable .</detailed_description>
	<mesh_term>Tolvaptan</mesh_term>
	<criteria>1 . Healthy define free significant cardiac , pulmonary , gastrointestinal , hepatic , biliary , renal , hematological , neurological psychiatric disease determine history , physical examination clinical laboratory test result . 2 . Male female 18 40 year age inclusive , time signing informed consent . 3 . A female eligible enter participate study : i. Nonchild bear potential ( i.e . postmenopausal , surgically sterile , bilateral tubal ligation , oophorectomy ) ; ii . Child bear potential , negative serum pregnancy test screening , negative urine pregnancy test admission day , certifies compliance one following : Complete abstinence intercourse 2 week prior administration study drug , throughout study , 3 day completion premature discontinuation study account elimination study drug ; Sterilization monogamous male partner ; Oral contraceptive subject take continuously least three month prior study ; Any FDA approve nonhormonal intrauterine device ( IUD ) ; 4 . Within 20 % ideal body weight base subject 's height ( inch ) weight ( kg ) . 5 . Willing able give write informed consent prior enter study . 1 . Participated another study within 30 day study period . 2 . A serum sodium le 135 mEq/L screen study day 1 8 study schedule . 3 . A positive urine serum pregnancy test , currently breastfeed . 4 . A history intestinal surgery gastrointestinal disorder may affect drug absorption . 5 . Any clinically significant abnormal result screen blood test , ECG , physical exam . 6 . Use CYP3A4 inhibitor inducer medication , juice , herbal supplement within 96 hour prior study period . 7 . Use oral intravenous antibiotic within 14 day study period . 8 . A current history alcohol drug abuse . 9 . Any alcohol consumption within 24 h prior study day 1 8 study schedule .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Bioavailability</keyword>
</DOC>